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Abstract Historically, patients with high risk prostate
cancer were considered poor candidates for radical prosta-
tectomy (RP) due to the likelihood of positive pelvic lymph
nodes and decreased long term survival. Although there is
still no consensus on the optimal therapy for this group of
patients, there is increasing evidence that surgery could
play a role. Cancer speciWc survival (CSS) rates after RP
for locally advanced disease at 10 year follow up range
from 29 to 72%, depending on tumor diVerentiation. The
role of pelvic lymph node dissection (PLND) in prostate
cancer remains a controversial topic. Nonetheless, in con-
junction with RRP extended PLND (ePLND) should be
performed as extended lymph node dissection in lieu of
standard PLND may increase staging accuracy, inXuence
decision making with respect to adjuvant therapy and possi-
bly impact outcome. High risk patients with organ conWned
prostate cancer and low volume (micro)metastatic disease
may be the ones to proWt most from this approach.
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Introduction
Historically, patients with high risk prostate cancer were
considered poor candidates for radical prostatectomy (RP)
due to the likelihood of positive pelvic lymph nodes and
decreased long term survival [1, 2]. Although there is still
no consensus on the optimal therapy for this group of
patients, there is increasing evidence that surgery could
play a role. The initiation of PSA screening, has led to stage
migration and improved outome after RP rekindling the
interest in surgery as an option for patients with high risk
prostate cancer. In locally advanced disease (cT3) the can-
cer speciWc survival (CSS) rate after RP at 10 year follow
up is 57–72% [1, 3, 4]. Tumor diVerentiation is an impor-
tant confounding factor and in well diVerentiated and mod-
erately diVerentiated cT3 tumors CSS rates at 10 years
range from 67–85%, however in poorly diVerentiated
tumors CSS rates sink to approx. 29% [1, 4].
The role of pelvic lymph node dissection (PLND) in
prostate cancer remains a controversial topic. There is no
doubt that an adequate PLND improves staging and as a
consequence allows better assessment of the disease and
it’s prognosis. It’s beneWcal eVect on disease progression
and survival, however can be questioned, especially in
patients with low risk prostate cancer. Patients with high
risk prostate cancer may be the ones most likely to proWt
from ePLND, especially those with micrometastatic dis-
ease. Patients with more extensive lymph node metastases
may beneWt from androgen deprivation therapy (ADT) [5].
DeWnition of high risk prostate cancer
The deWnition of high risk prostate cancer varies through-
out the literature. Where some consider a PSA >20 ng/ml
or a Gleason sum >7 or primary Gleason pattern of four or
Wve or clinical stage T3a to be high risk, others consider a
PSA ¸ 15 ng/ml, ¸ cT3 or biopsy Gleason score >7 high
risk prostate cancer [6, 7]. The AUA clinical guidelines
deWne high risk as a PSA >20 ng/mL or a Gleason score
of 8–10 or clinical stage ¸ T2c [8]. Using eight diVerent
deWnitions of high risk prostate cancer Yossepowitch et al.
F. C. Burkhard (&) · U. E. Studer
Department of Urology, University of Bern, 
Inselspital, Bern, Switzerland
e-mail: Wona.burkhard@insel.ch123
232 World J Urol (2008) 26:231–236[9] assessed a study population of 4,708 men treated by
RRP and concluded that: “patients diagnosed with high risk
prostate cancer by currently available deWnitions do not
have a uniformly poor prognosis after radical prostatec-
tomy”. Of the high risk tumors 22–63% proved to be con-
Wned to the prostate, 7–23% had lymph node metastasis and
the 5 year relapse free probability after RP was 49%. The
conclusion was that in high risk prostate cancer, RP mono-
therapy may be an acceptable treatment option and that
many cancers in this group are conWned to the prostate.
PSA values are not speciWc for prostate cancer, however
PSA dynamics may be. Both a short PSA doubling time
and an increased PSA velocity have been associated with
poor prognosis, however clear cut deWnitions are still lack-
ing [10, 11]. Although PSA dynamics may well prove to be
one of the most important factors to help predict patients at
risk of death from prostate cancer, they are not likely to
reXect the actual course of disease in all patients. PSA
changes may only provide usefull information in a few
patients at a time when the disease is still localized and the
patient will truly proWt from treatment. Indeed many
patients without an accelerated PSA doubling time or
velocity at the time of local therapy with curative intent will
later progress [12]. In addition PSA negative tumors may
have misleading PSA values. To summarize, the deWnition
of high risk prostate cancer has yet to be standardized and
future eVorts need to be focused on developing methods to
discriminate between patients at high risk for relapse who
may beneWt from local therapy alone and those requiring an
aggressive combination therapy.
Clinical staging
Accurate staging deWnes the extent and location of disease,
helps predict malignant potential, inXuences decision mak-
ing with respect to therapeutic options and possibly has an
impact on outcome. EVorts are being made to improve pre-
operative diagnosis of lymph node metastasis and so mini-
mize surgical risks and costs. Predictive nomograms that
help estimate the likelihood of positive nodes for each indi-
vidual patient by assigning points for speciWc risk factors
have been developed. However, most of these nomograms
are based on limited PLND and therefore their applicability
is questionable. They may be adequate to estimate the inci-
dence of positive nodes in a limited Weld of resection, they
do not however reXect the true probability of lymph node
metastases.
Recently, Briganti et al. found that the risk of positive
nodes in men undergoing RRP increases linearly in propor-
tion to the number of lymph nodes removed, hereby con-
Wrming previous observations by other authors [13, 14].
They then proceeded to develop and validate a nomogram
that predicts the probability of lymph node invasion based
on clinical parameters (PSA level, clinical stage, biopsy
Gleason score sum) and the number of nodes removed dur-
ing PLND [15]. The aim of this nomogram is to estimate
the optimal number of nodes that should be removed. As
with all other nomograms its accuracy depends on the
cohort used for it’s development. For one the majority of
patients included qualify as low risk patients and 9% (total
71 patients) were lymph node positive, this rather small
number limiting the signiWcance. In addition, true ePLND
was performed only in 23% of patients and this combined
with the knowledge that primary lymphatic drainage sites
may go up to the inferior mesenteric artery which was not
accounted for in the nomogram may again limit it’s reliabil-
ity [16]. In knowledge of the interindividual variability of
lymph node distribution, it appears easier to either perform
an ePLND including the known areas of prostatic drainage
or to omit PLND. Furthermore, the aim of PLND should
not only be to determine if a patient has positive nodes, but
also to remove as many nodes as possible. Nomograms can
only attempt to predict the probability of Wnding positive
nodes in a large series of patients and their value for the
individual patient remains questionable. The use of CT
scans or MRI to evaluate lymph node involvement is not
routinenly recommended as the low sensitivity of 10–30%
for imaging pelvic lymph node metastases is not acceptable
in high risk patients [17].
The sentinel lymph node (SLN) concept has been
applied to various malignant tumors. The SLN a term intro-
duced by Cabanas [18] is the node where lymphatic Xow
from the tumor Wrst arrives. Wawroschek et al. [19] intro-
duced the radioisotope method for detection of SLN in
prostate cancer. In their study the SLN method and the con-
secutive lymphadenectomy showed an apparently high sen-
sitivity rate of 96%. However the study had certain
weaknesses. The gamma probe needs to be in very close
contact with the tissue to get a good signal and lymph nodes
outside the area explored or with a weak signal may be
missed. Since it is known that a signiWcant number of posi-
tive nodes are also found along the internal iliac vessels, the
common iliac vessels, in the presacral and paraaortic tissue,
areas which were not all explored, some could have been
missed with the possibility of incomplete sampling [16, 20,
21]. Takashima et al. [22] using the SLN technique were
only able to detect in vivo 40% of the hot nodes detected ex
vivo after extended PLND. Anatomic localization of pros-
tatic sentinel nodes with fusion imaging of single photon
emission computed tomography (SPECT) and CT scans
after intraprostatic injection of Technetium-99m-Nanocol-
loid may be a more reliable imaging technique but is time
consuming, costly and is dependent on the skills of the
nuclear medicine specialist [23]. In addition in signiWcant
nodal disease technetium uptake can be compromised so123
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new and potentially promising techniques such as high res-
olution MRI with lymphotrophic superpara-magentic nano-
particles are being developed and evaluated, however
detection of micrometastasis remains limited and these
techniques are as yet not available [25]. The inability to
accurately diagnose minor lymph node metastasis preoper-
atively and the important prognostic information gained by
identifying nodal disease emphasizes the role of extended
PLND during radical retropubic prostatectomy (RRP).
Where to look for the nodes in high risk prostate cancer
A standardized universal deWnition of limited/ extended
PLND for prostate cancer does not exist. The minimal tem-
plate only includes lymphatic tissue from the obturator
fossa, the standard variant also includes lymphatic tissue
along external iliac vein. Extended PLND additionally
includes lymphatic tissue along the internal iliac vessels
both medially and laterally and in some cases along the
common iliac vessels. The next question is where to look
for the positive nodes. Evidence suggests that increased
lymph node sampling outside the obturator fossa may
increase the detection of metastatic disease. Heidenreich
et al. [26] reported on 103 patients who had an extended
PLND comprising the external iliac, internal iliac, obtura-
tor, and common iliac lymph nodes bilaterally and the pre-
sacral nodes. They compared this group of patients with
100 men who received only standard PLND. Lymph node
metastases were diagnosed in 26% in the extended group
and in only 12% in the standard PLND group. Despite neg-
ative obturator LN, positive LN were identiWed in the inter-
nal iliac and presacral regions. Forty-two percent of all LN
metastases were detected outside the regions of standard
PLND. Wawroschek et al. by extending the region of lym-
phadenectomy to include not only the tissue in the external
iliac region and fossa obturatoria but also the tissue along
the internal iliac vessels, in the paravesical, presacral and
pararectal tissue they detected an additional 35% of lymph
node positive patients [27]. Our group reported the results
following meticulous PLND along the external iliac vein,
the obturator nerve, and the internal iliac (hypogastric) ves-
sels in men with clinically organ-conWned disease. Eighty-
eight of 365 men (24%) had positive LN. Internal iliac LN
were positive in 58% and internal iliac LN alone were posi-
tive in 19% of the men [20]. Similar results have been
reported using the laparoscopic approach [28]. Stone et al.
[28] reported twice as many LN removed via extended than
limited laparoscopic PLND (mean 17:8 vs. 9.3), and three
times as many patients with LN metastasis in the extended
group [23.1 vs. 7.3% (p = 0.02)]. However, the link
between the extent and the yield of PLND was not always
conWrmed. The only randomized study on extended versus
limited PLND was reported by Clark et al. [29], who found
no diVerence in the yield of positive nodes with more
extended dissection (extended: 3.2% vs. limited: 2.4%).
The two types of dissection were conducted in the same
patient on contralateral sides, however, the majority of
patients had a low probability of LN metastases and there-
fore would not have required a PLND. Comparing these
two techniques in a cohort who are unlikely to have posi-
tive LN obviously limits the power of the trial. Even with-
out this limitation, the number of patients examined was
inadequate for an equivalence study. In addition, 90% of
their patients had T1c or T2a disease, which is mostly a
unilateral disease, and therefore randomly assigning them
to extended PLND on only one side carries a substantial
risk that the extended PLND was performed on the non
tumor bearing side. Also, neither the number of nodes
removed, nor the histopathological work-up were deWned.
Therefore, the study design renders it hard to compare their
data with those of other previous studies or draw any conlu-
sions for high risk patients.
A consensus on terminology of PLND is desperately
needed. In addition as a result of new insights the optimal
extent of PLND is continually being redeWned. Recent data
using intraprostatic technetium injections and fused single-
photon emission tomography (SPECT) combined with
either CT or MRI to map lymphatic drainage from the pros-
tate showed that the prostate has multiple landing sites and
that the extended template may need modiWcation as poten-
tially 30–40% of the lymphatic landing sites are not
included if PLND is limited to the iliac vessels distal the
bifurcation of the common iliac artery [16]. By extending
the dissection along common iliac vessels at least up to the
ureteric crossing approximately 75% of all nodes poten-
tially harbouring metastasis can be removed (Fig. 1).
Taken together, the above data shows that, in general,
extended PLND yields higher rates of positive LN. Impor-
tantly, several studies demonstrated that up to two thirds of
all patients with LN metastasis have positive nodes along the
internal iliac vessels, an area not included in a limited PLND.
A PLND, should therefore always include at least the internal
iliac tissue on both sides, so identifying LN invasion that
would remain undetected following limited PLND. By
extending the template to include the tissue along the com-
mon iliac vessels up to the ureteric crossing 75% of all nodes
potentially harbouring metastases are removed.
Therapeutic consequences of extended PLND
While a therapeutic beneWt of PLND has been questined by
some authors, the possibility of a therapeutic beneWt for
PLND in prostate cancer has been suggested by others.123
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between the extent of PLND and prostate cancer outcome
in LN negative men, nor did they Wnd a survival diVerence
when comparing the results of extended PLND (14 nodes
removed) between 1987 and 1989 with those of a more lim-
ited PLND (5 nodes removed) from 1999 to 2000. How-
ever, possible T-stage migration, with higher tumor stages
in the earlier period, was not taken into account. Because an
extended PLND in the earlier period led to similar results
for disease progression and survival as removing fewer
nodes in the later period, their results may ultimately imply
that the extended PLND had a therapeutic role for the ear-
lier cohort. Recently, Masterson et al. [31] examined the
association between the number of LNs removed, the num-
ber of positive LNs and disease progression in patients with
clinically localized prostate cancer. They found that in men
without nodal involvement an increased number of nodes
removed correlated signiWcantly with freedom from bio-
chemical recurrence. Similarly, Joslyn and colleagues,
using the SEER database, concluded that patients with LN
involvement had a signiWcantly greater number of nodes
removed compared with those with no LN involvement and
that extended PLND reduces the long-term risk of prostate
cancer related death, even in patients with negative nodes
compared to patients without PLND [14]. Recently Bader
et al. [13] demonstrated that the rate of tumor progression is
higher in pN0 patients with few nodes removed than in
patients with a larger number of negative nodes removed. A
potential explanation for these observations is that a thor-
ough nodal resection eliminated micrometastases that were
not detected by routine histologic examination. This
hypothesis is reported by recent studies applying special
assays to determine occult metastasis in pathologically
lymph node negative patients [32–34]. These investigators
found occult metastasis in up to 30% of patients and con-
cluded that a signiWcant beneWt in biochemical recurrence-
free survival might exist for patients with micrometastases
in a few nodes undergoing an extended dissection. It seems
therefore that not only detection of diseased nodes but
removal of as many primary lymphatic landing sites as pos-
sible should be the main objective for PLND to improve
outcome.
This is supported by further evidence indicating that
patients with minimal LN metastases will have better prog-
nosis by removing the diseased nodes. Golimbu and
coworkers [35] retrospectively analyzed 42 patients with
nodal disease who underwent PLND and RRP. In this
series, patients with low tumor bulk and one positive LN
had survival rates comparable to those of matched controls
after a mean follow-up of 5 years. Catalona suggested that
treatment may be curative even in LN positive disease,
however the 6 year follow up may be too short to allow a
deWnite statement. In a small series of 12 patients with LN
involvement and no adjuvant therapy, 75% remained recur-
rence free at 5 years and 58% at 7 years [36]. The results
reported by Pound et al. [37] for patients with LN microme-
tastasis, revealed a 10-year metastasis-free survival rate of
68%, again without adjuvant therapy. In 2003, Bader et al.
reported on 92 men followed with histologically proven LN
metastases who received no adjuvant therapy. After
45 months (median), 15 of 39 patients with only one posi-
tive node remained without signs of progression [38].
Recently Boorjian and colleagues [39] retrospectively
reviewed a large series of patients with positive lymph
nodes after RRP and PLND, although with a limited num-
ber of nodes (median 11) removed. The majority of the
node positive patients received androgen deprivation ther-
apy. In their series 56% of the patients had a 10 year BPFS.
In Pagliarulos group of initially node negative high risk
patients with immunohistochemically detected occult
lymph node metastasis there was an estimated 39% proba-
bility of remaining biochemically disease free for 10 years
[34]. This did not diVer signiWcantly from the group of
patients who were pathologically lymph node positive.
Interestingly after a median observation time of 12.9 years
only half of the patients with PSA relapse also developed
clinical recurrence.
Fig. 1 a Primary landing sites of the prostate determined by intrapros-
tatic technetium injections and fused single-photon emission tomogra-
phy (SPECT) combined with either CT or MRI. b Proposed template
including tissue along the common iliac vessels up to the crossing of
the ureter123
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of positive nodes involved. Daneshmand et al. [40] reported
that patients who had one or two positive LNs had a clinical
recurrence-free survival rate of 70 and 73% at 10 years. In
our series 10 and 14% of patients with two or more positive
LN remained disease free [38]. By contrast, men with Wve
or more involved nodes had a recurrence-free survival rate
of only 49%. Boorjian found that one lymph node metasta-
sis increased the risk of cancer speciWc death almost 4-fold,
which in patients with two or greater positive lymph nodes
was increased 2-fold compared to that in patients with one
positive node [39].
Opponents of extended PLND argue that performing an
extended PLND results in increased morbidity and costs
[41]. Morbidity can be minimized if attention is paid to a
few details: (1) Ligation of lymphatic vessels coming from
the legs, instead of clipping. Hemoclips have a tendency to
be torn away during subsequent surgery. (2) Placement of
two drains one on each side of the pelvis where PLND was
performed. Drains should be removed gradually until the
total amount drained is less than 50 ml/24 h. (3) Injection
of low molecular heparin into the upper arm instead of the
thigh.
Conclusions
There is evidence suggesting that RRP monotherapy is a
treatment option in selected high risk patients. In conjunc-
tion with RRP extended PLND should be performed as
extended lymph node dissection in lieu of limited PLND
may increase staging accuracy, inXuence decision making
with respect to adjuvant therapy and possibly impact out-
come. High risk patients with localized prostate cancer and
low volume (micro)metastatic disease may be the ones to
proWt most from this approach.
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